Bicycle Therapeutics News

Novartis' Pluvicto Expected to Dominate Prostate Cancer Radiopharmaceutical Market

Seeking Alpha16:00 ET

Jefferies Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $56

Moomoo NewsSep 19 08:33 ET · Ratings

Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC) and Radnet (RDNT)

TipRanksSep 19 08:10 ET · Ratings

A Quick Look at Today's Ratings for Bicycle Therapeutics(BCYC.US), With a Forecast Between $32 to $55

Moomoo NewsSep 16 09:00 ET · Ratings

Bicycle Therapeutics (BCYC) Receives a Buy From TD Cowen

TipRanksSep 16 07:46 ET · Ratings

Reported Saturday, Bicycle Therapeutics Announced Updated Phase 1/2 Results For Zelenectide Pevedotin (Formerly BT8009) In Metastatic Urothelial Cancer, BT5528 In Advanced Solid Tumors And BT7480 In Advanced Solid Tumors

BenzingaSep 16 04:51 ET

Bicycle Therapeutics Presents Updated Clinical Results Across Oncology Pipeline at ESMO Congress 2024

BusinesswireSep 14 03:00 ET

European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading

MT NewswiresSep 11 11:20 ET

Buy Rating for Bicycle Therapeutics Amid Promising Zelenectide Pevedotin Clinical Data

TipRanksSep 11 02:06 ET · Ratings

ADRs Advance; Bicycle Therapeutics Ltd. Climbs 28%

Dow JonesSep 9 16:30 ET

Needham Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $38

Moomoo NewsSep 9 12:32 ET · Ratings

Express News | Cantor Fitzgerald Reiterates Overweight on Bicycle Therapeutics

BenzingaSep 9 08:55 ET

Oppenheimer Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $48

Moomoo NewsSep 9 08:31 ET · Ratings

Barclays Maintains Bicycle Therapeutics(BCYC.US) With Buy Rating, Maintains Target Price $40

Moomoo NewsSep 9 04:33 ET · Ratings

Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone

BenzingaSep 6 13:37 ET

RBC Capital Initiates Bicycle Therapeutics(BCYC.US) With Buy Rating, Announces Target Price $35

Moomoo NewsSep 5 17:32 ET · Ratings

Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BusinesswireSep 3 16:05 ET

Bicycle Therapeutics (NASDAQ:BCYC) Shareholders Have Earned a 26% CAGR Over the Last Five Years

Yahoo FinanceAug 29 06:49 ET

European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading

MT NewswiresAug 22 11:07 ET

European Equities Traded in the US as American Depositary Receipts Trend Slightly Higher in Wednesday Trading

MT NewswiresAug 21 11:22 ET